QIAGEN N.V. today announced results for the third quarter of 2025 and reaffirmed its outlook for solid profitable growth while raising its profitability targets. QIAGEN reaffirmed its FY 2025 outlook ...
Native Infrared Spectroscopy spectroscopy produces high-resolution molecular maps of live cells and cell organelles.
The company's initial target is immuno-oncology projects but there are plans to expand into autoimmune disease, infectious disease, and more.
Completed enrollment in Phase 2 LOTUS trial of AVTX-009 for the treatment of hidradenitis suppurativa; topline data expected mid-2026Appointed Kevin Lind to Board of DirectorsExpanded leadership team ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback